Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

Completed · Phase 3

Conditions studied: Gastroesophageal Reflux Disease (GERD)

In brief

Study to assess the effects of adding tegaserod to PPI therapy results in clinically meaningful improvement of GERD symptoms in patients with incomplete relief of symptoms on daily PPI therapy alone.

Key facts

Study ID

NCT00171418

Run by

Novartis

People needed

54

Starts

2003-06-01

Expected to finish

2005-02-01

Last updated by the study team

2008-01-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• GERD symptoms for at least 6 months
• PPI therapy for at least 4 weeks
• Incomplete symptom relief on daily PPI therapy
• No erosive disease as evidenced in EGD/no change in symptom severity

You may not qualify if…

• Evidence of structural abnormality of the gastrointestinal tract or disease/conditions
• Previous gastrointestinal surgery that may influence esophageal motor function
• Known primary esophageal motor disorder other than Inefficient Esophageal Motor Disorder
• Evidence of cathartic colon or a history of laxative use
• Other protocol-defined inclusion/exclusion criteria may apply.

Where it is running

• Drug Research Services, Inc — Metairie, Louisiana, United States
• The Oklahoma Foundation for Digestive Research — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.